Ewa Gogola
Wellcome Early Career Fellow & Nicholas Kurti JRF (Brasnose College)
I joined the Patel lab after completing my PhD at the Netherlands Cancer Institute in Amsterdam, the Netherlands, where I studied PARP inhibitor resistance in BRCA1/2-deficient cancers. I am currently a Wellcome Trust Early-Career Award Fellow investigating tissue-specific responses to endogenous DNA damage and their contributions to tissue homeostasis and ageing. I am particularly interested in DNA damage-induced whole genome duplication and polyploidy.
Recent publications
-
A histone deacetylase 3 and mitochondrial complex I axis regulates toxic formaldehyde production.
Wit N. et al, (2023), Sci Adv, 9
-
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D. et al, (2022), Nature, 608, 609 - 617
-
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M. et al, (2021), Molecular cell, 81, 4692 - 4708.e9
-
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E. et al, (2019), Cancer Cell, 35, 950 - 952
-
Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
Gogola E. et al, (2019), Annual Review of Cancer Biology, 3, 235 - 254